Navigation Links
New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes

effects. Telmisartan has a longer duration of action than all other members of the ARB class; it takes approximately 24 hours for half the dose of telmisartan to be eliminated from the body compared to five to 15 hours for other ARBs.(7,8) Telmisartan is 99.5% bound to serum protein and is excreted almost entirely via non-renal pathways. Clinical trials have shown that telmisartan provides powerful and consistent blood pressure reduction over a full 24 hour period.(7-10)

About Telmisartan (Micardis(R)/Kinzal(R)/Pritor(R))

Telmisartan is a member of the angiotensin II receptor blocker (ARB) class and is being investigated in the most ambitious and far-reaching research programme ever conducted with an ARB. In the clinical trial programmes PROTECTION, ONTARGET and PRoFESS, over 58,000 patients have been enrolled to investigate the cardiovascular protective effects of Telmisartan.

Telmisartan was discovered and developed by Boehringer Ingelheim. Under the trademarks Micardis(R) and MicardisPlus(R) (combination with HCTZ) the company markets Telmisartan in 84 countries around the world, including the USA, Japan and European countries. Telmisartan is marketed in cooperation with Astellas Pharma Inc. in Japan, Bayer HealthCare in Europe and GlaxoSmithKline in selected markets. Bayer HealthCare promotes Telmisartan under the brand names Kinzalmono(R), Kinzalkomb(R) (combination with HCTZ), and Pritor(R) and PritorPlus(R) in markets across Europe. Pritor(R) and PritorPlus(R) is also marketed by GlaxoSmithKline in selected markets.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and almost 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to resea
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/14/2009)... Corgenix Medical Corporation (OTC Bulletin Board: CONX), ... test kits, and BG Medicine, Inc. (BGM), ... today a supply agreement whereby Corgenix will ... immunosorbent assay (ELISA) microtiter format exclusively for ... clearance in the United States of the ...
(Date:12/14/2009)... LLC ("Southridge"), an investment firm that provides financing ... that its affiliated fund has closed a private agreement ... financing to Imaging Diagnostic Systems, Inc. (OTCBB: IMDS). ... of Imaging Diagnostic Systems, Southridge has paved a way ... field of early breast cancer detection," said Stephen Hicks, ...
(Date:12/14/2009)... 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. ... had received a complete response letter from the ... its New Drug Application ("NDA") for Onrigin(TM) (laromustine) ... indicates that the FDA cannot approve the Company,s ... to address remaining issues. ,, Alan Kessman, Chief ...
Breaking Medicine Technology:Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc. 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3Actress Soleil Moon Frye Cant Be Punkd 3B NFL Star Terrell Owens Upset in Final Minutes of Alzheimers Association Contest 58724 1Actress Soleil Moon Frye Cant Be Punkd 3B NFL Star Terrell Owens Upset in Final Minutes of Alzheimers Association Contest 58724 2Vital Therapies Initiates Liver Stabilization Trial 58719 1Vital Therapies Initiates Liver Stabilization Trial 58719 2Robbins 26amp 3B Myers Announces Regular Quarterly Cash Dividend 5181 1
... Results Reflect Continued Investment in Clinical Development of TPI 287, ... TPPH ) announced today financial results for,the second quarter ended ... quarter of 2007 was $6.2 million, or $0.37,per share. This ... 2006 of,$4.2 million, or $0.28 per share. Included in the ...
... DOV Pharmaceutical,Inc. ("DOV" or the "Company") (Pink ... 21,947, its lead triple reuptake inhibitor ("TRIP") for,the ... the study,results indicates DOV 21,947 was safe and ... decline in plasma triglyceride levels.,The Company intends to ...
Other Medicine Technology:Tapestry Reports Second Quarter 2007 Results 2Tapestry Reports Second Quarter 2007 Results 3Tapestry Reports Second Quarter 2007 Results 4Tapestry Reports Second Quarter 2007 Results 5Tapestry Reports Second Quarter 2007 Results 6DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947 2DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947 3DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947 4DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947 5
(Date:12/14/2009)... years under government controlled health care, before moving to the U.S. ... and in his new book, Health Reform: The End of the ... system and its threat to real health care! , ... ... diagnostic radiologist from Minnesota, warns Americans not to sell out their ...
(Date:12/14/2009)... Tide of Tens of Thousands of New Chronic ... Legislation approved by Congress providing for ... in helping to reduce tens of thousands of ... the United States, the National Viral Hepatitis ... was included in the FY 2010 Consolidated Appropriations ...
(Date:12/14/2009)... hadn,t spread, study finds , , MONDAY, Dec. 14 (HealthDay ... death in male colon cancer survivors, researchers report. , ... men who,d been treated for stage I, stage II ... (nonmetastatic cancer). Every two years, the men were sent ... disease diagnoses, as well as their physical activity. A ...
(Date:12/14/2009)... -- Type 2 diabetes and obesity are linked to ... studies suggested that insulin glargine (a synthetic insulin preparation ... with a higher risk of certain cancers than other ... studies were unable to control for important factors such ... , On the other hand, a large randomized trial ...
(Date:12/14/2009)... Biopsy , ... Newport News, VA ... that the U.S. Food and Drug Administration (FDA) has granted ... guidance. , , ,GammaLMc® is a complementary technology to ... (GL) system will help doctors accurately locate breast lesions and ...
Breaking Medicine News(10 mins):Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 2Health News:Dilon Diagnostics Gamma-Guided Localization System Cleared by FDA 2
... on patients' family members rather than interpreters to provide ... School of Medicine, the Baltimore Examiner reports. ... pediatrics fellow at Johns Hopkins School of Medicine, and ... Pediatrics and found that 58% of physicians use bilingual ...
... UK’s Health Secretary has tendered an apology to thousands of junior ... a BBC program, Hewitt acknowledged that the new online system had ... should have been”. ,She was quoted: “That is ... and distress and I am very sorry indeed that has happened. ...
... malaise, say researchers. It can lead a person to ... ,What stood out most from this work of the researchers ... King's College London was the finding that depression was akin to ... up to five times. And to be noted ,was that this ...
... nearly 20% of the population in most economically developed countries. ... ,Dr Jo Bright and Dr John Hancock of the ... nitric oxide (NO) and nitrite is released by pollen grains, ... allergic response in the nose. Their research will be presented ...
... getting worse, but she wrote it off as just a ... time of the month// .” ,“I was increasingly ... pain,” says Ruma, 43. ,After running some tests, ... that affects one in 10 women, usually of childbearing age. ...
... mostly older male veterans suffering from chronic obstructive pulmonary ... to lung cancer, researchers found that regular use of ... developing lung cancer. ,David H. Au, M.D., M.S., ... in Seattle, along with five associates found that among ...
Other Medicine News:Health News:Health Secretary Apologizes For Failed Online Recruitment System 2Health News:Being Sad Can Kill You 2Health News:Hope for Ending the Pain, Infertility of Endometriosis? 2Health News:Hope for Ending the Pain, Infertility of Endometriosis? 3Health News:High Dose Inhaled Corticosteroid Use for COPD Could Cut Risk of Lung Cancer 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: